Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial.
Clin Cancer ResSep 1, 2026
Jonathan McConathy, Vadim S Koshkin, Yusuf Menda et al.
✦ AI-curated · Sources linked
In 30 seconds
The Phase I LuMIERE trial evaluated the safety of [177Lu]Lu-FAP-2286 in 27 heavily pretreated patients with advanced solid tumors. The study identified a recommended phase II dosage of 9.25 GBq, with 40.7% of patients experiencing grade ≥3 treatment-emergent adverse events. The trial demonstrated preliminary efficacy with one partial response and stable disease in ten patients.
Key findings
- Two dose-limiting toxicities were observed, including grade 4 lymphopenia and grade 3 hemoptysis.
- 40.7% of patients reported all-cause grade ≥3 treatment-emergent adverse events.
- The recommended phase II dosage for 177Lu-FAP-2286 was determined to be 9.25 GBq.
- One patient achieved a partial response, while ten maintained stable disease.
Why it matters
This study highlights the potential of targeting fibroblast activation protein in advanced solid tumors, providing a foundation for further investigation into the safety and efficacy of radiopharmaceutical therapies in this patient population.